PA
DSGN icon

Parallel Advisors’s Design Therapeutics DSGN Stock Holding History

Parallel Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-102
Closed -$643 – 3396
2023
Q2 		$643 Buy
102
+52
+104% +$318 ﹤0.01% 3047
2023
Q1 		$289 Buy
+50
New +$374 ﹤0.01% 3238

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Parallel Advisors's DSGN Position: Q3 2023 in Review

Parallel Advisors sold out of Design Therapeutics (DSGN) in Q3 2023, closing a stake of 102 shares — an estimated $643 sold.

Parallel Advisors first reported a position in DSGN in Q1 2023 and held it in 2 quarters. The position peaked at $643 in Q2 2023. 87 funds tracked by Wall St. Rank hold DSGN as of Q3 2023.

  • Parallel Advisors reported no remaining Design Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Parallel Advisors sold 102 Design Therapeutics shares in Q3 2023, an estimated $643.
  • Parallel Advisors first reported a position in Design Therapeutics in Q1 2023 and held it in 2 quarters.
  • Parallel Advisors's Design Therapeutics position peaked at $643 in Q2 2023.
  • 87 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2023.

Based on Parallel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.